Read previous post:
Oncolytics CEO Thompson: "To the best of our knowledge, this is the first successful double-blinded randomized data from a clinical study using an intravenously-administered oncolytic virus."
Oncolytics Biotech spikes after positive Reolysin Data

Shares of Oncolytics Biotech (TSX:ONC) are up nearly 35% this morning after announcing positive top line data from a Phase...